HUM vs. VTRS: A Head-to-Head Stock Comparison
Updated onHere’s a clear look at HUM and VTRS, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.
Company Profile
Symbol | HUM | VTRS |
---|---|---|
Company Name | Humana Inc. | Viatris Inc. |
Country | United States | United States |
GICS Sector | Health Care | Health Care |
GICS Industry | Health Care Providers & Services | Pharmaceuticals |
Market Capitalization | 35.74 billion USD | 12.30 billion USD |
Exchange | NYSE | NasdaqGS |
Listing Date | December 31, 1981 | March 17, 1980 |
Security Type | Common Stock | Common Stock |
Historical Performance
This chart compares the performance of HUM and VTRS by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period. Data is adjusted for dividends and splits.
Historical Performance at a Glance
Symbol | HUM | VTRS |
---|---|---|
5-Day Price Return | 3.10% | -1.22% |
13-Week Price Return | 30.84% | 24.12% |
26-Week Price Return | 11.93% | -3.48% |
52-Week Price Return | -16.22% | -9.83% |
Month-to-Date Return | 18.94% | 20.71% |
Year-to-Date Return | 17.14% | -15.26% |
10-Day Avg. Volume | 1.46M | 8.78M |
3-Month Avg. Volume | 1.78M | 12.06M |
3-Month Volatility | 40.32% | 31.14% |
Beta | 0.46 | 0.91 |
Profitability
Return on Equity (TTM)
HUM
9.02%
Health Care Providers & Services Industry
- Max
- 26.03%
- Q3
- 13.74%
- Median
- 8.26%
- Q1
- 4.13%
- Min
- -3.62%
HUM’s Return on Equity of 9.02% is on par with the norm for the Health Care Providers & Services industry, indicating its profitability relative to shareholder equity is typical for the sector.
VTRS
-19.92%
Pharmaceuticals Industry
- Max
- 38.59%
- Q3
- 19.84%
- Median
- 11.90%
- Q1
- 5.63%
- Min
- -9.96%
VTRS has a negative Return on Equity of -19.92%. This indicates the company is generating a loss for its shareholders, which can be a result of unprofitability or negative shareholder equity and is often a sign of financial distress.
Net Profit Margin (TTM)
HUM
1.28%
Health Care Providers & Services Industry
- Max
- 12.40%
- Q3
- 5.93%
- Median
- 1.96%
- Q1
- 0.93%
- Min
- -6.10%
HUM’s Net Profit Margin of 1.28% is aligned with the median group of its peers in the Health Care Providers & Services industry. This indicates its ability to convert revenue into profit is typical for the sector.
VTRS
-24.57%
Pharmaceuticals Industry
- Max
- 34.51%
- Q3
- 17.73%
- Median
- 12.12%
- Q1
- 5.99%
- Min
- -7.73%
VTRS has a negative Net Profit Margin of -24.57%, indicating the company is operating at a net loss as its expenses exceeded its revenues.
Operating Profit Margin (TTM)
HUM
2.68%
Health Care Providers & Services Industry
- Max
- 19.05%
- Q3
- 10.21%
- Median
- 4.22%
- Q1
- 1.98%
- Min
- -4.27%
HUM’s Operating Profit Margin of 2.68% is around the midpoint for the Health Care Providers & Services industry, indicating that its efficiency in managing core business operations is typical for the sector.
VTRS
-26.54%
Pharmaceuticals Industry
- Max
- 41.53%
- Q3
- 23.00%
- Median
- 16.24%
- Q1
- 9.24%
- Min
- -6.94%
VTRS has a negative Operating Profit Margin of -26.54%. This signifies the company is unprofitable at the operational level, as its core business expenses exceed its revenue.
Profitability at a Glance
Symbol | HUM | VTRS |
---|---|---|
Return on Equity (TTM) | 9.02% | -19.92% |
Return on Assets (TTM) | 3.19% | -8.50% |
Net Profit Margin (TTM) | 1.28% | -24.57% |
Operating Profit Margin (TTM) | 2.68% | -26.54% |
Gross Profit Margin (TTM) | -- | 40.15% |
Financial Strength
Current Ratio (MRQ)
HUM
0.01
Health Care Providers & Services Industry
- Max
- 2.01
- Q3
- 1.49
- Median
- 1.30
- Q1
- 0.94
- Min
- 0.17
HUM’s Current Ratio of 0.01 is notably low, falling beneath the typical range for the Health Care Providers & Services industry. This suggests a heightened liquidity risk and could indicate potential challenges in meeting its short-term obligations.
VTRS
1.37
Pharmaceuticals Industry
- Max
- 4.49
- Q3
- 2.77
- Median
- 1.74
- Q1
- 1.26
- Min
- 0.11
VTRS’s Current Ratio of 1.37 aligns with the median group of the Pharmaceuticals industry, indicating that its short-term liquidity is in line with its sector peers.
Debt-to-Equity Ratio (MRQ)
HUM
0.69
Health Care Providers & Services Industry
- Max
- 2.17
- Q3
- 1.18
- Median
- 0.74
- Q1
- 0.45
- Min
- 0.00
HUM’s Debt-to-Equity Ratio of 0.69 is typical for the Health Care Providers & Services industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.
VTRS
0.82
Pharmaceuticals Industry
- Max
- 2.44
- Q3
- 1.07
- Median
- 0.42
- Q1
- 0.11
- Min
- 0.00
VTRS’s Debt-to-Equity Ratio of 0.82 is typical for the Pharmaceuticals industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.
Interest Coverage Ratio (TTM)
HUM
3.61
Health Care Providers & Services Industry
- Max
- 14.47
- Q3
- 7.15
- Median
- 5.45
- Q1
- 2.04
- Min
- -4.44
HUM’s Interest Coverage Ratio of 3.61 is positioned comfortably within the norm for the Health Care Providers & Services industry, indicating a standard and healthy capacity to cover its interest payments.
VTRS
-0.13
Pharmaceuticals Industry
- Max
- 103.95
- Q3
- 44.18
- Median
- 9.83
- Q1
- 2.82
- Min
- -42.71
VTRS has a negative Interest Coverage Ratio of -0.13. This indicates that its earnings were insufficient to cover even its operational costs, let alone its interest payments, signaling significant financial distress.
Financial Strength at a Glance
Symbol | HUM | VTRS |
---|---|---|
Current Ratio (MRQ) | 0.01 | 1.37 |
Quick Ratio (MRQ) | 0.01 | 0.65 |
Debt-to-Equity Ratio (MRQ) | 0.69 | 0.82 |
Interest Coverage Ratio (TTM) | 3.61 | -0.13 |
Growth
Revenue Growth
EPS Growth
Dividend
Dividend Yield (TTM)
HUM
1.25%
Health Care Providers & Services Industry
- Max
- 5.38%
- Q3
- 2.22%
- Median
- 0.55%
- Q1
- 0.00%
- Min
- 0.00%
HUM’s Dividend Yield of 1.25% is consistent with its peers in the Health Care Providers & Services industry, providing a dividend return that is standard for its sector.
VTRS
4.58%
Pharmaceuticals Industry
- Max
- 6.98%
- Q3
- 3.32%
- Median
- 2.13%
- Q1
- 0.14%
- Min
- 0.00%
With a Dividend Yield of 4.58%, VTRS offers a more attractive income stream than most of its peers in the Pharmaceuticals industry, signaling a strong commitment to shareholder returns.
Dividend Payout Ratio (TTM)
HUM
14.15%
Health Care Providers & Services Industry
- Max
- 186.69%
- Q3
- 74.82%
- Median
- 26.76%
- Q1
- 0.00%
- Min
- 0.00%
HUM’s Dividend Payout Ratio of 14.15% is within the typical range for the Health Care Providers & Services industry, suggesting a balanced approach between shareholder payouts and company reinvestment.
VTRS
137.04%
Pharmaceuticals Industry
- Max
- 165.20%
- Q3
- 90.59%
- Median
- 49.13%
- Q1
- 28.91%
- Min
- 0.00%
VTRS’s Dividend Payout Ratio of 137.04% is in the upper quartile for the Pharmaceuticals industry. This indicates a strong commitment to shareholder returns but also suggests that a smaller portion of earnings is retained for reinvestment compared to many peers.
Dividend at a Glance
Symbol | HUM | VTRS |
---|---|---|
Dividend Yield (TTM) | 1.25% | 4.58% |
Dividend Payout Ratio (TTM) | 14.15% | 137.04% |
Valuation
Price-to-Earnings Ratio (TTM)
HUM
21.85
Health Care Providers & Services Industry
- Max
- 55.89
- Q3
- 30.85
- Median
- 21.17
- Q1
- 12.63
- Min
- 0.00
HUM’s P/E Ratio of 21.85 is within the middle range for the Health Care Providers & Services industry. This suggests its valuation is in line with the sector average, representing neither a significant premium nor a discount compared to its peers.
VTRS
--
Pharmaceuticals Industry
- Max
- 42.51
- Q3
- 26.88
- Median
- 19.11
- Q1
- 15.12
- Min
- 0.00
P/E Ratio data for VTRS is currently unavailable.
Price-to-Sales Ratio (TTM)
HUM
0.28
Health Care Providers & Services Industry
- Max
- 3.10
- Q3
- 1.74
- Median
- 0.67
- Q1
- 0.24
- Min
- 0.00
HUM’s P/S Ratio of 0.28 aligns with the market consensus for the Health Care Providers & Services industry. This suggests its valuation, based on sales, is seen as standard and is on par with its competitors.
VTRS
0.88
Pharmaceuticals Industry
- Max
- 7.55
- Q3
- 4.54
- Median
- 2.11
- Q1
- 1.52
- Min
- 0.00
In the lower quartile for the Pharmaceuticals industry, VTRS’s P/S Ratio of 0.88 indicates its revenue is valued more conservatively than most of its peers. This could present a compelling opportunity if the market has overlooked its sales-generating capabilities.
Price-to-Book Ratio (MRQ)
HUM
1.62
Health Care Providers & Services Industry
- Max
- 7.61
- Q3
- 4.32
- Median
- 2.53
- Q1
- 1.14
- Min
- 0.77
HUM’s P/B Ratio of 1.62 is within the conventional range for the Health Care Providers & Services industry. This shows a balanced market view, where the stock’s price is neither at a significant premium nor a discount to the book value of its peers.
VTRS
0.67
Pharmaceuticals Industry
- Max
- 9.78
- Q3
- 4.96
- Median
- 2.23
- Q1
- 1.46
- Min
- 0.60
VTRS’s P/B Ratio of 0.67 is in the lower quartile for the Pharmaceuticals industry. From a value investing perspective, this is favorable, as it suggests the stock is trading at a discount to its net asset value and may offer a greater margin of safety.
Valuation at a Glance
Symbol | HUM | VTRS |
---|---|---|
Price-to-Earnings Ratio (TTM) | 21.85 | -- |
Price-to-Sales Ratio (TTM) | 0.28 | 0.88 |
Price-to-Book Ratio (MRQ) | 1.62 | 0.67 |
Price-to-Free Cash Flow Ratio (TTM) | 11.03 | 7.29 |